BMO Capital Markets Cuts Aveanna Healthcare (NASDAQ:AVAH) Price Target to $10.00

Aveanna Healthcare (NASDAQ:AVAH) had its price objective lowered by stock analysts at BMO Capital Markets from $11.00 to $10.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 53.02% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. Zacks Research cut Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price objective for the company in a research note on Friday. Barclays lifted their target price on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Truist Financial lowered their target price on Aveanna Healthcare from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Friday. Finally, William Blair began coverage on shares of Aveanna Healthcare in a research note on Monday, December 8th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.81.

Aveanna Healthcare Stock Performance

AVAH traded up $0.20 on Friday, hitting $6.54. 994,112 shares of the company’s stock were exchanged, compared to its average volume of 1,198,656. The firm has a market cap of $1.37 billion, a PE ratio of 18.18 and a beta of 2.07. The stock has a fifty day moving average of $7.88 and a two-hundred day moving average of $8.50. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. Aveanna Healthcare has a twelve month low of $3.73 and a twelve month high of $10.32.

Insider Buying and Selling

In other Aveanna Healthcare news, insider Patrick A. Cunningham sold 18,436 shares of Aveanna Healthcare stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $132,923.56. Following the sale, the insider owned 337,755 shares in the company, valued at $2,435,213.55. The trade was a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeff Shaner sold 173,225 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $1,248,952.25. Following the transaction, the chief executive officer owned 2,650,892 shares of the company’s stock, valued at $19,112,931.32. This trade represents a 6.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 998,595 shares of company stock valued at $7,567,770. 7.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aveanna Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of AVAH. Caitong International Asset Management Co. Ltd lifted its holdings in Aveanna Healthcare by 252.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after acquiring an additional 2,400 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Aveanna Healthcare by 1,001.5% in the fourth quarter. Invesco Ltd. now owns 360,464 shares of the company’s stock valued at $2,945,000 after purchasing an additional 327,738 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of Aveanna Healthcare by 12.7% during the fourth quarter. Mackenzie Financial Corp now owns 216,200 shares of the company’s stock worth $1,810,000 after buying an additional 24,447 shares during the period. Zimmer Partners LP bought a new position in shares of Aveanna Healthcare during the fourth quarter worth about $6,189,000. Finally, Voloridge Investment Management LLC acquired a new stake in Aveanna Healthcare in the 4th quarter valued at approximately $1,915,000. 87.96% of the stock is owned by institutional investors.

Key Headlines Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q4 results materially beat estimates — Aveanna reported revenue of $662.5M (up ~27% YoY) and an EPS beat (reported $0.83 vs. consensus near $0.13). The strong top‑line growth and big EPS beat are the main bullish catalysts. GlobeNewswire Q4 Results
• Positive Sentiment: Raymond James upgraded AVAH from Outperform to Strong‑Buy and set a $13 price target (~~97% above the recent price), which likely boosted investor demand and sentiment. Finviz (Raymond James Upgrade)
• Neutral Sentiment: Earnings call / transcripts available for detail — Investors can review management’s commentary on margins, organic growth and reimbursement trends in the Q4 call transcript to assess sustainability of recent results. Earnings Call Transcript
• Neutral Sentiment: Short‑interest data in recent reports appears unreliable/zeroed out (reported as 0 shares), so it doesn’t provide a clear signal on positioning or potential squeezes at the moment.
• Negative Sentiment: Fiscal‑2026 revenue/growth outlook disappointed some analysts and investors — coverage noted that the company’s revenue outlook trailed consensus, which pressured the stock despite the Q4 beat. That guidance miss is the main bearish offset to today’s gains. MSN (Guidance Miss)
• Negative Sentiment: Some outlets flagged the fiscal‑2026 guidance update as a reason for intracday weakness after the initial pop, highlighting that near‑term growth assumptions and reimbursement dynamics will be key watchpoints for investors. TipRanks (Guidance & Outlook)

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.